BBIO vs JAZZ
BridgeBio Pharma, Inc. and Jazz Pharmaceuticals plc, both Healthcare
Jazz Pharmaceuticals plc is the larger company at $14B against $14B. Over the past year JAZZ returned +70% against +25% for BBIO. The RyuScore puts JAZZ ahead, 48 against 7 out of 100.
| Figure | BBIO | JAZZ |
|---|---|---|
| Last close | $65.35 | $218 |
| Market cap | $14B | $14B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 14.9 |
| 1-year return | +25% | +70% |
| 5-year return | +34% | +62% |
| RyuScoresector-relative, 1–10 | 7/100 | 48/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Jazz Pharmaceuticals plc
Revenue of $1.2B in Q2 2026, net income $193M. Its largest reported line is Oncology, 31% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.